Early Real-World Outcomes Among US Patients (Pts) with IgAN Receiving Atrasentan: APPRISE-IgAN Data Platform (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0661; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Funding Commercial Support – Novartis Pharmaceuticals Corporation Background A Pt Platform for Real-world data on Iptacopan and Atrasentan in the United StatEs for pts with IgAN (APPRISE-IgAN) captures real-world data on US pts with IgAN prescribed atrasentan (selective endothelin type A receptor antagonist) and/or iptacopan (complement factor B inhibitor). Conclusion In this real-world study, atrasentan showed meaningful proteinuria and hematuria reduction in a subgroup of SGLT2i-experienced population with IgAN, suggesting early clinical benefit. Ongoing data collection will provide further information."
Clinical • Real-world • Real-world evidence • Fibrosis • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Immunology • Renal Disease • CFB
|
|
Mohanram Narayanan; Briana C. Ndife; Helen Trenz; Manny Dance; Ruth Haile-Meskale; Neema Stephens; Claire Buchan; Tayler Buchan; Eugene Baraka; Pietro A. Canetta
|